Park Jin Hyuk stood in front of the microphone.

Mao Dayong and Shi Zhengwan also came on stage and stood behind him.

After the sound of camera shutters gradually subsided, Park Jin Hyuk spoke:

"There are many journalists here today. I would like to introduce myself first. I am Park Jin Hyuk, chairman of DS Telecom."

After saying this, Park Jin Hyuk bowed and continued:

"I only learned about this press conference after arriving at headquarters this morning. I can tell everyone is very concerned about the production volume of Bidafil. Before I answer this question, let me first explain why I am the one answering this question."

In the venue, everyone's eyes were focused on Park Jin Hyuk.

"It was during my time at DS Pharmaceuticals that I, under my leadership, secured the production and sales rights for Bidafil, the Paris flu-curing drug, from Novo Nordisk Pharmaceuticals. I subsequently coordinated production with Novo Nordisk Pharmaceuticals and determined production volumes, so I'm very familiar with Bidafil's production."

Park Jin Hyuk paused and continued:

"First of all, I don't think expanding production is a top priority right now. DS Pharmaceuticals is supplying Bifida to the market in an orderly manner according to plan. We are not intentionally creating drug shortages, nor will we raise prices simply because of increased demand. At the same time, even if demand were to surge exponentially, we have no plans to increase supply. DS Pharmaceuticals is advancing all aspects of its work in an orderly manner. I hope the journalists present and the public watching the live broadcast will trust us and give us a little more time."

Before Park Jin Hyuk finished speaking, reporters bombarded him with questions.

"Not only our country, but other neighboring countries are also facing a shortage of Bidaphil. Although DS Pharmaceuticals has its own plans, shouldn't it consider changes in market demand?"

Park Jin Hyuk replied:

"Currently, Bidaphil is produced by DS BioLogics, a subsidiary of DS Pharmaceuticals. DS BioLogics produces more than just this one drug. If all of its production capacity is devoted to Bidaphil, patients with other diseases may face the problem of having no available medicine. This is unacceptable to us."

"If DS BioLogics' production capacity is insufficient, why can't it transfer the production rights to other companies?"

"You have to know that we obtained exclusive production rights from Novo Nordisk Pharmaceuticals. We obtained these rights after extremely difficult negotiations and paid a lot for it. Now asking us to easily transfer these rights is probably not in line with basic business rules."

"As an entrepreneur, shouldn't you consider the public interest at this time? Make sacrifices to solve the supply problem of Bidafel."

"What I want to say is that Bidafil is not a panacea. The Ministry of Health and Welfare has repeatedly warned the public not to stockpile medications, and we strongly agree with that."

"Are you going to continue to ignore the demands of the general public?"

"I don't think the majority opinion is necessarily correct. We have a plan in place and will proceed with all work in an orderly manner according to the plan."

…

The press conference lasted for one hour.

Facing reporters' questions, Park Jin Hyuk answered in a humble and polite manner, sticking to his original position from beginning to end.

Many people watched the press conference through television broadcast.

"As far as I know, DS BioLogics will be going public in a few days. Some believe that under the current circumstances, DS BioLogics' stock price is likely to fall below the issue price after the listing. How do you plan to deal with this possible situation?"

Faced with this question, Park Jin Hyuk lowered his head and fell into thought.

Of all the questions the reporter asked, this one was the most troubling to him.

After a brief thought, he replied:

"We are currently discussing countermeasures to this issue. I am very confident in the future of BioLogics. While there will always be problems during development, they are temporary. I believe DS BioLogics will be able to overcome the difficulties it faces. The press conference has now concluded. Thank you all for your participation. Today's press conference concludes."

After saying this, Park Jin Hyuk bowed and walked down from the podium.

After leaving the venue, Park Jin Hyuk turned around and asked Shi Zhengwan who had followed him:

"President Shi, is there any latest progress on the listing?"

"We have finalized the offering price with DS Securities at RMB (approximately 185 yuan) per share, but considering the various issues we are currently facing... we estimate the share price will fall by around 10% after listing."

"10%? I'm afraid it will fall even more... So, what's the plan to stabilize the stock price?"

"DS Securities is saying that it expects the stock price to continue to fluctuate during the first three months of listing and that it is best to wait and see and then take action once the stock price stabilizes."

"I have a bad feeling about this, but I hope nothing serious will happen."

Despite this situation, Park Jin Hyuk does not think there is anything wrong with the decision to go public early.

However, if the confidence of shareholders who have already subscribed for shares is shaken, DS BioLogics may become a target of short selling and the company's image will suffer severe damage.

"You need to continue to pay attention to market trends. If BioLogics's listing goes awry, it could be more fatal than the production cuts."

This chapter is not over yet, please click on the next page to continue reading!